Recent advances in adrenocortical carcinoma in adults

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 3, 2013, Pages 192-197

  Bourdeau, Isabelle ^a   MacKenzie Feder, Jessica ^a   Lacroix, André ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adrenocortical cancer; Chemotherapy; Cushing's syndrome; Genetics; Mitotane

Indexed keywords

2 [FLUORINE 18]FLUORO 2 DEOXY DEXTRO GLUCOSE; ALDOSTERONE; BETA CATENIN; CISPLATIN; CORTICOSTEROID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUORINE 18; METOMIDATE; MITOTANE; SOMATOMEDIN B; SORAFENIB; STREPTOZOCIN; SUNITINIB; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION; HUMAN; LUNG METASTASIS; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); METASTASIS RESECTION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; COMBINED MODALITY THERAPY; HUMANS; PROGNOSIS;

EID: 84879216935     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283602274     Document Type: Review

References (57)

1. Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab 2010; 95:4812-4822.
2. Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011; 60:1055-1065.
3. Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011; 7:323-335.
4. Mazzuco TL, Durand J, Chapman A, et al. Genetic aspects of adrenocortical tumours and hyperplasias. Clin Endocrinol (Oxf) 2012; 77:1-10.
5. Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol 2012; 351:66-70.
6. Palmero EI, Achatz MIW, Ashton-Prolla P, et al. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 2010; 22:64-69.
7. Bougeard G, Sesboue R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008; 45:535-538.
8. Herrmann LJ, Heinze B, Fassnacht M, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97:E476-E485.
9. Raymond VM, Else T, Everett JN, et al. Prevalence of Germline TP53 Mutations in a Prospective Series of Unselected Patients with Adrenocortical Carcinoma. J Clin Endocrinol Metab 2013; 98:E119- E125.
10. Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775-3784.
11. Deandreis D, Leboulleux S, Caramella C, et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2011; 2:354-362.
12. Zhang HM, Perrier ND, Grubbs EG, et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrastenhanced studies. Clin Radiol 2012; 67:38-46.
13. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 2011; 259:117-126.
14. Gust L, Taieb D, Beliard A, et al. Preoperative 18F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors. World J Surg 2012; 36:1406- 1410.
15. Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006; 91:920-925. (Pubitemid 43357759)
16. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:2665- 2671. (Pubitemid 44024634)
17. Hahner S, Sundin A. Metomidate-based imaging of adrenal masses. Horm Cancer 2011; 2:348-353.
18. Hennings J, Lindhe O, Bergstrom M, et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 2006; 91:1410- 1414.
19. Hahner S, Kreissl MC, Fassnacht M, et al. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97:914-922.
20. Hermsen IG, Kerkhofs TM, den Butter G, et al. Surgery in adrenocortical carcinoma: Importance of national cooperation and centralized surgery. Surgery 2012; 152:50-56.
21. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12:667-680. (Pubitemid 41483000)
22. Porpiglia F, Miller BS, Manfredi M, et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011; 2:372-377.
23. Leboulleux S, Deandreis D, Al Ghuzlan A, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 2010; 162:1147-1153.
24. Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010; 57:873-878.
25. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58:609-615.
26. Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012; 255:363-369.
27. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery 2012; 152: 123-132.
28. Kemp CD, Ripley RT, Mathur A, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg 2011; 92:1195-1200.
29. op den Winkel J, Pfannschmidt J, Muley T, et al. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. Ann Thorac Surg 2011; 92:1965-1970.
30. Ripley RT, Kemp CD, Davis JL, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol 2011; 18:1972- 1979.
31. Datrice NM, Langan RC, Ripley RT, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012; 105:709- 713.
32. Erdogan I, Deutschbein T, Jurowich C, et al. The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. J Clin Endocrinol Metab 2013; 98:181-191.
33. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372-2380. (Pubitemid 46883771)
34. Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95:4925-4932.
35. Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 2010; 28:e401-e402.
36. Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011; 96:1844-1851.
37. Volante M, Terzolo M, Fassnacht M, et al. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clin Cancer Res 2012; 18:3452-3461.
38. Kroiss M, Quinkler M, Lutz WK, et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2011; 75:585-591
39. Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces cyp3a4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98:161-171.
40. Zatelli MC, Gentilin E, Daffara F, et al. Therapeutic concentrations of mitotane (o, p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 2010; 151:2453-2461.
41. Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:4501-4504. (Pubitemid 44833430)
42. Sabolch A, Feng M, Griffith K, et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 2011; 80:1477-1484.
43. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005; 12:657-666. (Pubitemid 41482999)
44. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000; 11:1281-1287.
45. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366:2189-2197.
46. Butler C, Butler WM, Rizvi AA. Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract 2010; 16:441-445.
47. Kroiss M, Quinkler M, Johanssen S, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 2012; 97:3495-3503.
48. Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008; 93:2057-2062. (Pubitemid 351831515)
49. Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010; 65:765-773.
50. Barlaskar FM, Spalding AC, Heaton JH, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009; 94:204-212.
51. Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009; 15:668-676.
52. de Reynies A, Assie G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009; 27:1108-1115.
53. Fragoso MC, Almeida MQ, Mazzuco TL, et al. Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur J Endocrinol 2012; 166:61-67.
54. Masi G, Lavezzo E, Iacobone M, et al. Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors. J Endocrinol Invest 2009; 32:597-600.
55. Tadjine M, Lampron A, Ouadi L, Bourdeau I. Frequent mutations of betacatenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 2008; 68:264-270.
56. Tissier F, Cavard C, Groussin L, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005; 65:7622-7627. (Pubitemid 41297234)
57. Gaujoux S, Grabar S, Fassnacht M, et al. beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 2011; 17:328-336.